Raluca Budiu-Predoiu

Raluca Budiu-Predoiu is a skilled professional in the field of oncology and precision medicine, currently serving as the Companion Diagnostics Strategy Lead and Director of Precision Medicine IO at AbbVie since September 2022. Prior experience includes a significant role at Merck from August 2014 to September 2022 as Principal Scientist in Translational Oncology, where Raluca Budiu-Predoiu acted as the biomarker lead for several cancer types and collaborated on external studies. Earlier roles include Associate Principal Scientist at Mount Sinai School of Medicine and Scientist at the University of Pittsburgh, where Raluca Budiu-Predoiu contributed to innovative cancer research, including the development of a triple transgenic mouse model and a new vaccine. Raluca Budiu-Predoiu's academic background includes a PhD in Biology from Babes-Bolyai University, completed in 2007.